Aims: Paddy field is one of the sources of greenhouse gasses such as methane (CH4) and nitrous oxide (N2O), which causes global warming and other negative effects in agricultural sector. An alternative to optimize paddy productivity and reduce emissions of CH4 and N2O is by using methanotrophic bacteria and Ochrobactrum anthropi BL2. Methodology and results: This study consisted of two parts, i.e. positive control and experimental treatments. Positive control consisted of 250 kg/ha NPK inorganic fertilizer NPK (15:15:15) (100% of the recommended normal dose) without any methanotrophic bacteria. Meanwhile the experimental treatment consisted of 50 kg/ha inorganic fertilizers NPK (20% of the recommended normal dose) with methanotrophic bacteria (Methylocystis rosea BGM 1, M. parvus BGM 3, Methylococcus capculatus BGM 9, Methylobacter sp. SKM 14) and N2O reducing bacteria (Ochrobactrum anthropi BL2). Using weight indicator of 1000 grams, all the bacteria are capable of increasing paddy productivity by 42.07%, compared to conventional method which can only increase the productivity by 2.51% (Cepy and Wangiyana, 2011). The increasing productivity and growth of paddy plants were due to the nitrogen fixation activity of M. rosea BGM 1, M. capculatus BGM 9, and Methylobacter sp. SKM 14. In the experimental treatment using bacteria, the emission of CH4 and N2O was reduced with the highest CH4 and N2O sinks of 24018.8 mol CH4/day/ha and 68.48 mol N2O/day/ha, respectively. However, the positive control treatment with 100% of the recommended fertilizer dose showed the highest CH4 and N2O emissions which were up to 74346.45 mol CH4/day/ha and 26.21 mol N2O/day/ha, respectively. Conclusion, significance and impact study: All the methanotropic bacteria and O. anthropi BL2 are significantly increase paddy production, compared to positive control treatment. The addition of bacteria in paddy fields results in CH4 and N2O sinks.
Ochrobactrum anthropi

Ochrobactrum anthropi, a rarely encountered organism in humans, is usually associated with infections in immunocompromised hosts and patients with indwelling catheters. We report a case of bacteremia associated with O. anthropi in a 80-year-old male with intrahepatic duct carcinoma. After insertion of biliary stent with endoscopic retrograde cholangiopancreatography, fever and neutrophilic leukocytosis developed in the patient. Blood cultures were performed three times, and O. anthropi was isolated from an aerobic bottle. Although the patient did not receive effective antibiotic treatment, fever and neutrophilic leukocytosis were improved.
Aged, 80 and over ; Bacteremia* ; Catheters, Indwelling ; Cholangiopancreatography, Endoscopic Retrograde ; Fever ; Humans ; Immunocompromised Host ; Leukocytosis ; Male ; Neutrophils ; Ochrobactrum anthropi* ; Ochrobactrum* ; Stents

Ochrobactrum anthropi is a ubiquitous gram-negative bacillus and currently thought to be an opportunistic pathogen. We experienced a 66-year-old male patient with continuous ambulatory peritoneal dialysis (CAPD)-related peritonitis caused by O. anthropi. Susceptible antibiotic therapy including amikacin and ciprofloxacin improved the patient's clinical status. However, peritoneal effluent showed sustained leukocytosis, thus CAPD catheter was removed. After 2 weeks of temporary hemodialysis, CAPD was successfully restarted with reinsertion of catheter. This is, to our knowledge, the first case of CAPD-related peritonitis caused by O. anthropi in Korea.
Aged ; Amikacin ; Bacillus ; Catheters ; Ciprofloxacin ; Humans ; Korea ; Leukocytosis ; Male ; Ochrobactrum ; Ochrobactrum anthropi ; Peritoneal Dialysis, Continuous Ambulatory ; Peritonitis ; Renal Dialysis

Ochrobactrum anthropi is an aerobic, gram-negative, motile, non-lactose-fermenting, oxidase-producing, and urease-positive bacillus. We reported a case of aortic valve endocarditis due to O. anthropi in a hemodialysis patient. To our knowledge, this is the first case of O. anthropi endocarditis in a hemodialysis patient in Korea. The organism was resistant to beta-lactam antibiotics and susceptible to ciprofloxacin, amikacin, trimethoprim-sulfamethoxazole, gentamicin and carbapenem. We treated O. anthropi endocarditis with meropenem for 6 weeks and the patient recovered completely.
Amikacin ; Anti-Bacterial Agents ; Aortic Valve ; Bacillus ; Ciprofloxacin ; Endocarditis ; Gentamicins ; Humans ; Korea ; Ochrobactrum ; Ochrobactrum anthropi ; Renal Dialysis ; Thienamycins ; Trimethoprim, Sulfamethoxazole Drug Combination

PURPOSE: To report a case of Ochrobactrum anthropi endophthalmitis following cataract extraction and intraocular lens implantation. METHODS: A 57-year-old man was refered for evaluation and management of chronic uveitis on his left eye. He had undergone cataract surgery 1 year previously. His visual acuity of left eye was 20/100. The left eye had marked inflammation in anterior chamber and vitreous cavity. We performed pars plana vitrectomy with removal of the intraocular lens and intravitreal antibiotics injection (Amikacin 0.4 mg/0.1 ml). RESULTS: Microbiologic examination of the anterior chamber fluid, intraocular lens disclosed Ochrobactrum anthropi, a gram-negative bacillus. Twelve weeks after vitrectomy, his left corrected visual acuity was 20/25 and anterior segment showed no inflammatory cell.
Anterior Chamber ; Anti-Bacterial Agents ; Aqueous Humor ; Bacillus ; Cataract Extraction ; Cataract* ; Endophthalmitis* ; Humans ; Inflammation ; Lens Implantation, Intraocular ; Lenses, Intraocular ; Middle Aged ; Ochrobactrum anthropi* ; Ochrobactrum* ; Uveitis ; Visual Acuity ; Vitrectomy

PURPOSE: To report polymicrobial keratitis involving Pseudomonas aeruginosa, Acinetobacter baumannii, and Ochrobactrum anthropi. CASE SUMMARY: A 53-year-old female complained of pain and secretion in her right eye, which started 6 weeks before her visit. She applied steroid ointment, which was received from the dermatologist, to her eyelid 7 days prior to her visit but this treatment worsened her symptoms. At the initial visit, the visual acuity of the right eye was light perception, and purulent secretions were observed. Using a slit lamp, severe conjunctival hyperemia, hypopyon, and a ring-shaped central corneal ulcer were observed. The anterior chamber and fundus were not observed due to corneal lesions but ultrasonography showed no intraocular inflammation. Infectious keratitis was suspected and cultured by corneal scraping. During the incubation period, 0.5% moxifloxacin, 2% voriconazole, and 1% cyclopentolate were administered. A total of 400 mg of moxifloxacin and 100 mg of doxycycline were given orally. In the primary culture, Pseudomonas aeruginosa and Acinetobacter baumannii were identified so 5% ceftazidime, which was sensitive for the antibiotic susceptibility results was further instilled. Thereafter, the keratitis improved but the keratitis again worsened while maintaining the topical treatment. A secondary culture was positive for Ochrobactrum anthropi. Treatment with 1.4% gentamicin, which was sensitive for the antibiotic susceptibility test was added and the keratitis improved. A conjunctival flap was performed because of the increased risk of perforation. CONCLUSIONS: We report polymicrobial keratitis involving Pseudomonas aeruginosa, Acinetobacter baumannii, and Ochrobactrum anthropi for the first time in the Republic of Korea.
Acinetobacter baumannii ; Acinetobacter ; Anterior Chamber ; Ceftazidime ; Corneal Ulcer ; Cyclopentolate ; Doxycycline ; Eyelids ; Female ; Gentamicins ; Humans ; Hyperemia ; Inflammation ; Keratitis ; Middle Aged ; Ochrobactrum anthropi ; Ochrobactrum ; Pseudomonas aeruginosa ; Pseudomonas ; Republic of Korea ; Slit Lamp ; Ultrasonography ; Visual Acuity ; Voriconazole

Ochrobactrum anthropi is an oxidase-producing, non-lactose-fermenting, gram-negative bacillus that is frequently isolated from the environment including sinks, baths, soil, and hospital water sources. Recently O. anthropi have been reported as an emerging opportunistic pathogen in immunocompromised patients, particularly in those with indwelling venous catheters. Most O. anthropi were highly resistant to beta-lactam antibiotics except carbapenem. We report a case of O. anthropi bacteremia with an unusual pattern of antibiotic resistance compared to previous reports. A 47-year-old woman undergoing camptobell/cisplatin chemotherapy via indwelling venous catheter (chemoport) for stage IV ovarian cancer, had septicemia due to O. anthropi of unknown origin. The isolates were resistant to all beta-lactams and meropenem and susceptible to aminoglycoside, ciprofloxacin, and trimethoprim-sulfamethoxazole. She recovered from sepsis with combination treatment with imipenem and ciprofloxacin for 3 weeks.
Anti-Bacterial Agents ; Bacillus ; Bacteremia ; Baths ; beta-Lactams ; Catheters ; Ciprofloxacin ; Drug Resistance, Microbial ; Female ; Humans ; Imipenem ; Immunocompromised Host ; Middle Aged ; Ochrobactrum ; Ochrobactrum anthropi ; Ovarian Neoplasms ; Sepsis ; Soil ; Thienamycins ; Trimethoprim, Sulfamethoxazole Drug Combination

Ochrobactrum anthropi is an oxidase-producing, non-lactose-fermenting, gram-negative bacillus that is frequently isolated from the environment including sinks, baths, soil, and hospital water sources. Recently O. anthropi have been reported as an emerging opportunistic pathogen in immunocompromised patients, particularly in those with indwelling venous catheters. Most O. anthropi were highly resistant to beta-lactam antibiotics except carbapenem. We report a case of O. anthropi bacteremia with an unusual pattern of antibiotic resistance compared to previous reports. A 47-year-old woman undergoing camptobell/cisplatin chemotherapy via indwelling venous catheter (chemoport) for stage IV ovarian cancer, had septicemia due to O. anthropi of unknown origin. The isolates were resistant to all beta-lactams and meropenem and susceptible to aminoglycoside, ciprofloxacin, and trimethoprim-sulfamethoxazole. She recovered from sepsis with combination treatment with imipenem and ciprofloxacin for 3 weeks.
Anti-Bacterial Agents ; Bacillus ; Bacteremia ; Baths ; beta-Lactams ; Catheters ; Ciprofloxacin ; Drug Resistance, Microbial ; Female ; Humans ; Imipenem ; Immunocompromised Host ; Middle Aged ; Ochrobactrum ; Ochrobactrum anthropi ; Ovarian Neoplasms ; Sepsis ; Soil ; Thienamycins ; Trimethoprim, Sulfamethoxazole Drug Combination

We report a case of spontaneous bacterial peritonitis from Ochrobactrum anthropi. O. anthropi is recognized as an emerging pathogen in immunocompromised patients. In contrast to most previously described cases, the patient reported here had no indwelling catheter. To our knowledge, no case of O. anthropi spontaneous bacterial peritonitis has been reported in the medical literature until now.
Treatment Outcome ; Rare Diseases/diagnosis/drug therapy/microbiology ; Peritonitis/*diagnosis/drug therapy/*microbiology ; Ochrobactrum anthropi/drug effects/*isolation & purification ; Middle Aged ; Male ; Humans ; Gram-Negative Bacterial Infections/*diagnosis/drug therapy/*microbiology ; Anti-Bacterial Agents/administration & dosage

The purpose of the study is to use O. intermedium DN2 to degrade nicotine in tobacco extracts for making reconstituted tobacco. Firstly, we studied the effects of various factors on degradation of nicotine in the extracts by strain DN2. When we added 0.1% yeast extract into the extracts, adjusted its pH value to 7.0 by ammonia solution, inoculated 15% cultures and maintained fermentation temperature of 30 degrees C, the degradation rate of nicotine by strain DN2 was the fastest. Furthmore, under these conditions, we studied the degradation rates of nicotine in three fed batches culture which carried out in a 30-L reactor, the result showed that the average degradation rate of nicotine by strain DN2 was 140.55 mg/L/h, which was much higher than that reported in other studies. These results indicated that strain DN2 may be useful for reducing nicotine content of reconstituted tobacco.
Nicotine ; metabolism ; Ochrobactrum ; classification ; metabolism ; Plant Extracts ; metabolism ; Tobacco ; chemistry